Combining Immunotherapies With Targeted Therapies and Other Immunotherapies

OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years in recurrent, fully resected osteosarcoma and lung metastases.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.

During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a patient with early relapsed diffuse large B-cell lymphoma.